Inflammatory bowel disease (IBD) is categorized into two subtypes: Crohn’s disease (CD) and ulcerative colitis (UC). The causes of IBD are unknown; however, the mechanism involves hyperactive immune-mediated inflammation. Some studies have shown a genetic aspect associated with the genetic influence on the microbiome’s composition, as well as common susceptible gene loci found in IBD patients influencing its pathogenesis [¹]. IBD is suspected through clinical symptoms and lab findings, however, the gold standard for the diagnosis is endoscopy/colonoscopy with a biopsy of the affected area showing specific histological features [²] In Crohn’s disease, the inflammation extends through all layers of the intestinal tissue and can affect any part of the intestinal tract, from mouth to anus. “Skipped lesions” are often seen, which is important when obtaining a tissue biopsy and determining the extent of the disease. In UC, inflammation is limited to the mucosal layer of the colon; commonly originating in the rectum and extending up to involve the entire colon continuously [³]. Complications unique to severe CD involve fistula formation, abscess formation, and strictures. A major complication unique to UC is toxic megacolon, which, if not treated immediately, can result in colon rupture and can lead to sepsis and death [⁴]. Inflammatory bowel disease (IBD) is widely accepted as one of the important risk factors leading to colorectal cancer (CRC). Patients with IBD are at a significantly increased risk of CRC, primarily due to the pro-neoplastic effects of chronic intestinal inflammation. The risk of CRC in IBD is influenced by factors such as disease duration, extent, and severity, the presence of inflammatory pseudopolyps, coexistent primary sclerosing cholangitis, and a family history of CRC [⁵].

Mycophenolate Mofetil (MMF) is a 2-morpholinoethyl ester, a prodrug that gets converted to mycophenolic acid (MPA). MPA is a non-competitive and reversible inhibitor of inosine monophosphate dehydrogenase, an enzyme involved in the purine biosynthesis pathway. Its effect on the de novo synthesis of purines allows it to play a role as an immunosuppressant [⁶]In earlier years, MMF was only FDA-approved for use in the prophylaxis of organ transplant rejection. Given its mechanism of action, MMF has since been used to treat a plethora of inflammatory/autoimmune conditions. Its first “off-label” use was for psoriasis. [⁷]. Many trials have then been done showing its efficacy and tolerability, and therefore it has become well-suited as a monotherapy or in combination with corticosteroids. MMF is also found to be effective in patients unresponsive or contraindicated to other immunomodulating agents, as well as in cases of steroid-sparing treatment. Overall, MMF is very well tolerated, with the most common side effects being gastrointestinal, diarrhea, nausea, and vomiting [⁸]. With the many variations in the presentation of Inflammatory bowel disease, as well as the variation in medication response and side effects, it’s important to consider all the possibilities to present to patients as a treatment plan. Mycophenolate mofetil is one immunomodulator that isn’t commonly used; however, given its mechanism of action, it may be a good option for certain individuals suffering from IBD. In this systematic review and meta-analysis, we aimed to study the efficacy and safety of MMF in managing resistant IBD, focusing on remission rates at eight weeks and six months, which is defined as the absence or significant reduction of symptoms associated with the disease.

This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines [⁹,¹⁰].

Our study encompassed a systematic search that ultimately yielded twelve eligible studies involving 446 patients with IBD, predominantly with Crohn’s disease (74.6%) and ulcerative colitis (23.9%). Patient demographics revealed an average age of 38.4 years, with males comprising 38.7% of the cohort. The meta-analysis unveiled promising outcomes: remission rates at 8 weeks (62.2%), 6 months (52.8%), and steroid-free remission (53.3%). Additionally, the pooled incidence of side effects was 26.1%, with nausea/vomiting being the most prevalent (21.2%). Discontinuation rates due to failure (29.7%) and intolerance (20%) were notable, underscoring the importance of adverse event management and treatment efficacy in IBD therapy.

As we continue to learn the multifactorial risk factors contributing to IBD, we must also investigate the right medications to manage this disease. Since each patient presents with IBD in a unique way, their medication responsiveness is just as unique. To better explore and understand the effectiveness and indications of Mycophenolate Mofetil in the treatment of inflammatory bowel disease, we included 12 high-quality articles. In these articles, there appears to be an effective treatment therapy with the use of MFF for IBD.

Aminosalicylates (5-ASA), whether administered orally or topically, are efficacious in both initiating and sustaining remission in cases of moderate UC. These medications sometimes give rise to adverse symptoms such as nausea, fever, and rash. Glucocorticoids are the preferred first treatment for moderate to severe UC to induce remission. However, they are not recommended for long-term maintenance due to their major adverse effects on several organs, such as Cushing’s syndrome (e.g., insulin resistance, high blood pressure, cataracts, avascular necrosis). The process of gradually reducing their dosage should be implemented while simultaneously introducing maintenance treatment [¹¹,¹²].

Immunomodulators, such as azathioprine (AZA) and its byproduct mercaptopurine, are glucocorticoid-sparing agents that may be introduced. The most common side effect is leukopenia and therefore all patients are required to have routine blood work. Biologics, including anti-TNF agents and monoclonal antibodies, have been proven to induce and maintain remission in moderate to severe UC. Risk factors of these agents include reactivation of latent infections such as TB and hepatitis B, and therefore, all patients must be worked up and treated for these infections before starting medication. Lastly, hospitalized patients can be started on cyclosporin, a calcineurin-inhibiting agent, when nonresponsive to IV glucocorticoids, with the most common side effects including hyperuricemia, hypertension, and gingival hyperplasia [¹³]. Treatment for CD varies from that of UC because of its intestinal tract involvement 5-ASA was only shown to be effective in mild CD with colon involvement. Glucocorticoids are effective in inducing remission in moderate to severe CD; however, just like in UC, they should not be used for maintenance therapy. Immunomodulators are also effective in CD as a glucocorticoid-sparing treatment; however, they have not been shown to induce remission. Methotrexate was found to be effective in maintaining.

remission and alleviating corticosteroid dependency; however, it puts patients at risk of interstitial pneumonitis and can cause hepatotoxicity. Biologics are recommended for moderate to severe CD, and are mostly effective as a combination therapy versus monotherapy [¹³].

Overall, our analysis studies have shown that MMF has been used particularly in patients who are steroid-dependent and are refractory or intolerant to more conventional therapies. A significant portion of patients are refractory to conventional therapies, making alternative management a hot topic. Studies were primarily conducted on IBD patients who were unresponsive, intolerant, or contraindicated for azathioprine. Patients often discontinue the drug due to unresponsiveness, resulting in disease relapse, or the event of undesired adverse effects such as pancreatitis, infections, and hepatitis. In a cross-sectional study by Lee et al., they discuss the intolerance of AZA as a predictor of a poor prognosis, indicating that patients with a more aggressive disease course [¹⁴]. Hassard et al. correlated resistance to AZA as a predictor of resistance to MMF, and resistance to AZA categorized patients as having severe IBD. Those unresponsive to AZA and MFF perhaps have an IBD that is resistant to the effects of purine synthesis inhibitors [¹⁵]Some studies have shown that patients have a deficiency in thiopurine methyltransferase (TPMT), the enzyme that metabolizes azathioprine. This reduction in the drugs’ metabolism increases the risk of bone marrow suppression, making AZA a poor option. [¹⁶].

The most undesirable reported adverse event with AZA is AZA-induced pancreatitis. In Fickert et al., 40% of the patients entered in the study after AZA-induced pancreatitis. Another patient was unable to start AZA because of prior mesalamine severe drug-induced pancreatitis, making AZA a poor option for them [²¹].

Miehsler et al compared two study groups and reported pancreatitis in 13% of patients, with another 10% showing elevated lipase in the group on AZA therapy. AZA-induced leukopenia occurred in 13% of the patients’ studies in Miehsler et al., whereas no patients on MMF were shown to have leukopenia. Additionally, Miehsler et al. reported the development of monoclonal gammopathy as a result of AZA. Not all side effects resolution was discussed; however, Fickert et al. report that all adverse reactions induced by AZA in the patient’s studies had disappeared after the discontinuation of the drug [²¹,²³].

Our results, pooled from this meta-analysis, concluded that remission rates vary across periods. The overall remission rate was 62.2% at 8 weeks (95% CI: 42.6%-78.5%); it was marginally lower at 52.8% at 6 months (95% CI: 36.6%-68.4%). The pooled rate for steroid-free remission was 53.3% (95% CI: 24.6%-80%). The results of this study emphasize the significance of taking into account the duration and course of treatment when evaluating remission rates in individuals diagnosed with UC. Ford et al. report successful control of IBD with MMF in 41% of the studied patients with an average of 18 months of therapy. All of these patients were on steroids at the time of initiating MMF; however, they were no longer on steroids at the time of review. This allows us to consider MMF as a bridge therapy to remission in refractory patients. Miehsler et al. reported a significant reduction in the cumulative intake of prednisone within the first 6 months of MMF use, compared to no reduction in the prednisone intake in those on AZA. This alone can help guide treatment options, as chronic steroid use is associated with very severe long-term side effects. If tapering and cessation of steroids can be achieved quickly with MMF, it may be more favorable to avoid long-term risks associated with prolonged steroid use. This earlier onset of the therapeutic effect of MMF is also seen in transplant survival studies comparing MMF and AZA, and the reduction of rejection episodes [²³].

In a study by Hernandez-Camba et al., clinical efficacy was seen in 71% of patients in whom MMF was added to their biologic regimen. This concomitant use of combined therapy can allow clinicians to consider adding MMF to a patient’s developing secondary non-response to anti-TNF alpha monotherapy. Furthermore, Fellermann et al. involved patients who were started on combined therapy of prednisone and MMF in the first block, followed by a decrease in prednisone and an increase in MMF in the second block. This helps us see the effects of dual therapy of prednisone for induction of remission, along with MMF as a bridge to monotherapy with just MMF. The study, however, reported decreased success as the steroids were tapered, indicating perhaps too early taper. Following this, those patients received a steroid pulse, and eventually, about 42% of patients reached remission and maintained remission after the steroid taper [²⁰]. This may reflect the delayed onset of drug onset, leading us to consider the length of therapy required to reach drug efficacy.

When introducing a drug for medical management, it is important to understand the possibility and likelihood of adverse events. Our analysis of overall adverse effects in twelve pooled studies reveals an incidence rate of 26.1% (95% CI: 20.3%-32.8%). Subgroup analysis further delineates specific adverse events, with nausea and vomiting being the most frequently reported side effects, with an overall rate of 21.2% (95% CI: 8.5%-43.9%). Arthralgia follows, with a pooled rate of 15.5% (95% CI: 7.9%-27.9%), while diarrhea and skin rash show rates of 13.6% (95% CI: 7.6%-23%) and 12.6% (95% CI: 5.2%-27.5%), respectively. Additionally, the incidence of infection and deranged liver function were reported at 12.6% (95% CI: 5%-28%) and 7.5% (95% CI: 2.8%-18.7%), respectively. These findings underscore the need for careful monitoring and management of adverse effects in UC treatment to optimize patient care and outcomes. In addition to the specific adverse effects reported, the rate of medication discontinuation due to intolerance is a critical aspect of treatment evaluation. The pooled rate of drug discontinuation attributable to intolerance was found to be 20% (95% CI: 12.3%-30.9%) in the context of the aforementioned adverse events. This highlights the significant impact of side effects on treatment adherence and underscores the importance of balancing efficacy with tolerability in UC management strategies. Efforts to minimize adverse events and improve patient tolerability are essential to reduce the likelihood of treatment discontinuation and optimize long-term therapeutic outcomes.

In contrast, thiopurines are associated with specific risks, such as leukopenia, pancreatitis, and hepatotoxicity, while biologics carry risks of infections and immunogenicity leading to loss of response [²⁷,²⁸]. However, without direct comparative studies, it remains challenging to definitively evaluate MMF’s safety profile relative to these therapies.

Clinical implications: Based on the comprehensive analysis of various treatment options and their associated adverse effects, MMF emerges as a promising alternative for patients who cannot tolerate other conventional steroid-sparing agents, such as azathioprine, or other medications for IBD. The study findings demonstrate MMF’s efficacy in inducing and maintaining remission, particularly in patients who are steroid-dependent or refractory to other therapies. Notably, MMF shows a favorable adverse effect profile compared to azathioprine, with lower rates of adverse events such as leukopenia and pancreatitis, which are common concerns with azathioprine therapy. Additionally, MMF may offer quicker tapering of steroid use, reducing the risk of long-term steroid-related complications. Furthermore, MMF can be combined with biological agents for patients experiencing secondary non-response, potentially enhancing treatment outcomes. Although MMF is not without its side effects, careful monitoring and management can help mitigate adverse events and optimize therapeutic benefits. Therefore, MMF represents a valuable treatment option for patients with IBD who have failed or cannot tolerate other medications, offering a potential pathway to achieve and maintain remission while minimizing the risk of treatment-related complications.

Limitations: This is a single-arm analysis with a lack of a control group, which makes it challenging to establish a causal relationship between the intervention and outcomes. Without a comparator, it’s difficult to determine whether observed effects are solely attributable to the intervention or influenced by other factors. Another limitation of this study is its focus on patients with steroid dependence and refractoriness or intolerance to conventional therapies, primarily azathioprine, within the IBD population as those patients do not fully represent the broader spectrum of patients with IBD who may respond differently to treatments or have different underlying conditions.

Recommendation: Existing studies have focused on MMF in refractory or steroid-dependent IBD patients, leaving a gap in evidence for its use in early disease management. To date, randomized controlled trials (RCTs) specifically evaluating MMF as a first-line therapy in newly diagnosed IBD patients are lacking. This absence of robust data limits our understanding of MMF’s safety, efficacy, and positioning in the early treatment algorithm for IBD. Consequently, new RCTs testing the efficacy and safety of MMF in newly diagnosed IBP patients are warranted.

In conclusion, our study shed light on the potential of MMF as a treatment option for IBD. Despite limitations, including a lack of a control group, our findings suggest that MMF holds promise, particularly for individuals who are steroid-dependent or refractory to conventional steroid-sparing therapies. MMF demonstrates efficacy in inducing and maintaining remission, with a favorable adverse effect profile compared to some traditional treatments like azathioprine. However, further research, particularly prospective randomized controlled trials comparing MMF to standard treatments, is needed to better understand its role in IBD management.